Literature DB >> 33879500

Clinical Implications of an Acute Dip in eGFR after SGLT2 Inhibitor Initiation.

Hiddo J L Heerspink1, David Z I Cherney2.   

Abstract

Entities:  

Keywords:  SGLT2 inhibitor; clinical nephrology; glomerularhyperfiltration glomerular filtration rate; sodium-glucose cotransporter2

Mesh：

Substances：

Year:  2021        PMID： 33879500      PMCID： PMC8455037          DOI： 10.2215/CJN.02480221

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  10 in total

Review 1.  Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.

Authors:  Lennart Tonneijck; Marcel H A Muskiet; Mark M Smits; Erik J van Bommel; Hiddo J L Heerspink; Daniël H van Raalte; Jaap A Joles
Journal:  J Am Soc Nephrol       Date:  2017-01-31       Impact factor: 10.121

2.  We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury.

Authors:  Vikas S Sridhar; Katherine R Tuttle; David Z I Cherney
Journal:  Am J Kidney Dis       Date:  2020-07-22       Impact factor: 8.860

3.  Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.

Authors:  A Perlman; S N Heyman; I Matok; J Stokar; M Muszkat; A Szalat
Journal:  Nutr Metab Cardiovasc Dis       Date:  2017-10-18       Impact factor: 4.222

Review 4.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

5.  Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.

Authors:  Kengo Kidokoro; David Z I Cherney; Andrea Bozovic; Hajime Nagasu; Minoru Satoh; Eiichiro Kanda; Tamaki Sasaki; Naoki Kashihara
Journal:  Circulation       Date:  2019-02-18       Impact factor: 29.690

6.  Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Authors:  Bettina J Kraus; Matthew R Weir; George L Bakris; Michaela Mattheus; David Z I Cherney; Naveed Sattar; Hiddo J L Heerspink; Ivana Ritter; Maximilian von Eynatten; Bernard Zinman; Silvio E Inzucchi; Christoph Wanner; Audrey Koitka-Weber
Journal:  Kidney Int       Date:  2020-11-10       Impact factor: 10.612

7.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Authors:  Frank A Holtkamp; Dick de Zeeuw; Merlin C Thomas; Mark E Cooper; Pieter A de Graeff; Hans J L Hillege; Hans-Henrik Parving; Barry M Brenner; Shahnaz Shahinfar; Hiddo J Lambers Heerspink
Journal:  Kidney Int       Date:  2011-03-30       Impact factor: 10.612

8.  Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study.

Authors:  Carina Iskander; David Z Cherney; Kristin K Clemens; Stephanie N Dixon; Ziv Harel; Nivethika Jeyakumar; Eric McArthur; Flory Tsobo Muanda; Chirag R Parikh; J Michael Paterson; Navdeep Tangri; Jacob A Udell; Ron Wald; Amit X Garg
Journal:  CMAJ       Date:  2020-04-05       Impact factor: 8.262

9.  Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

Authors:  Megumi Oshima; Meg J Jardine; Rajiv Agarwal; George Bakris; Christopher P Cannon; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Soo Kun Lim; Kenneth W Mahaffey; Bruce Neal; Carol Pollock; Norman Rosenthal; David C Wheeler; Hong Zhang; Bernard Zinman; Vlado Perkovic; Hiddo J L Heerspink
Journal:  Kidney Int       Date:  2020-12-11       Impact factor: 10.612

10.  Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.

Authors:  Min Zhao; Shusen Sun; Zhenguang Huang; Tiansheng Wang; Huilin Tang
Journal:  Clin J Am Soc Nephrol       Date:  2020-12-29       Impact factor: 8.237
  10 in total
  13 in total

Review 1.  Kidney and heart failure outcomes associated with SGLT2 inhibitor use.

Authors:  Annemarie B van der Aart-van der Beek; Rudolf A de Boer; Hiddo J L Heerspink
Journal:  Nat Rev Nephrol       Date:  2022-02-10       Impact factor: 28.314

2.  Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis.

Authors:  David Tak Wai Lui; Ivan Chi Ho Au; Eric Ho Man Tang; Ching Lung Cheung; Chi Ho Lee; Yu Cho Woo; Tingting Wu; Kathryn Choon Beng Tan; Carlos King Ho Wong
Journal:  EClinicalMedicine       Date:  2022-06-25

Review 3.  Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Authors:  Kevin Yau; Atit Dharia; Ibrahim Alrowiyti; David Z I Cherney
Journal:  Kidney Int Rep       Date:  2022-05-05

Review 4.  Considerations and possibilities for sodium-glucose cotransporter 2 inhibitors in pediatric CKD.

Authors:  Alexander J Kula
Journal:  Pediatr Nephrol       Date:  2022-01-27       Impact factor: 3.651

Review 5.  Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.

Authors:  Marcus Säemann; Daniel Cejka; Sabine Schmaldienst; Alexander R Rosenkranz; Gert Mayer
Journal:  Wien Klin Wochenschr       Date:  2022-10-17       Impact factor: 2.275

6.  Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.

Authors:  Simke W Waijer; Priya Vart; David Z I Cherney; Glenn M Chertow; Niels Jongs; Anna Maria Langkilde; Johannes F E Mann; Ofri Mosenzon; John J V McMurray; Peter Rossing; Ricardo Correa-Rotter; Bergur V Stefansson; Robert D Toto; David C Wheeler; Hiddo J L Heerspink
Journal:  Diabetologia       Date:  2022-04-21       Impact factor: 10.460

7.  Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.

Authors:  João Pedro Ferreira; Francisco Vasques-Nóvoa; Diana Ferrão; Francisca Saraiva; Inês Falcão-Pires; João Sérgio Neves; Abhinav Sharma; Patrick Rossignol; Faiez Zannad; Adelino Leite-Moreira
Journal:  Diabetes Care       Date:  2022-07-07       Impact factor: 17.152

8.  Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study.

Authors:  Fang-Ju Lin; Chi-Chuan Wang; Chien-Ning Hsu; Chen-Yi Yang; Chih-Yuan Wang; Huang-Tz Ou
Journal:  Cardiovasc Diabetol       Date:  2021-10-07       Impact factor: 9.951

9.  Efficacy and Safety of Dapagliflozin in Children With Inherited Proteinuric Kidney Disease: A Pilot Study.

Authors:  Jiaojiao Liu; Jingyi Cui; Xiaoyan Fang; Jing Chen; Weili Yan; Qian Shen; Hong Xu
Journal:  Kidney Int Rep       Date:  2021-12-21

Review 10.  Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?

Authors:  Aditi Ujjawal; Brittany Schreiber; Ashish Verma
Journal:  Ther Adv Endocrinol Metab       Date:  2022-04-13       Impact factor: 4.435
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.